Moderna, Thermo Fisher partner to manufacture Covid vaccine, other drugs
[BENGALURU] Moderna has entered into a long-term agreement with Thermo Fisher Scientific for the manufacturing of its Covid-19 vaccine and other experimental medicines based on mRNA technology, the companies said on Wednesday (Feb 23).
Thermo Fisher had already partnered with Moderna last year to help scale up production of its Covid vaccine, branded as Spikevax.
As a part of the 15-year expanded deal, Thermo Fisher would provide dedicated manufacturing capacity in the United States for fill/finish services as well as labeling and packaging services for Spikevax and other mRNA drugs in Moderna's pipeline.
Moderna's vaccine received full US approval in January for adults and is cleared for use in more than 70 countries.
The company last week said it was developing three new vaccines based on the same messenger RNA (mRNA) technology used for its Covid-19 shot, including one for viral infection shingles.
On Tuesday, Moderna also announced a partnership with Adium Pharma for the distribution of its vaccine in Latin America.
Moderna is set to report its fourth-quarter results on Thursday. REUTERS
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Share with us your feedback on BT's products and services
TRENDING NOW
Knight Frank Singapore CEO Galven Tan resigns after 2.5 years at helm
ABSD deadline extended to up to 7 years for developers of large en bloc sites to encourage reuse of land
15-month wait-out curb lifted for private property owners buying HDB resale flats
Philippines’ income upgrade hides grim reality for most Filipinos